In conclusion, we found that EZH2 inhibitors promote apoptosis in MM cell lines through the NF-κB signaling pathway and reduce TIGIT ligand CD155 expression on MM cell surfaces by inhibiting the mTOR signaling pathway. The gene discussed is NFKB1; the disease is Miyoshi myopathy.